MedTrace Logo

Extended Release Protein Dosing

NCT07313436 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-03-24

No results posted yet for this study

Summary

The overall goal of this study is to determine the minimum dose required to elicit measurable elevation of plasma essential amino acid levels 12 hours after consuming VitaKey's extended release protein technology. The results of this study will be used to set a dose for future protein clinical studies.

Conditions

  • Nutrition

Interventions

OTHER

Extended release nutritional protein

Participants will consume a beverage with extended release protein.

OTHER

Control

Participants will consume a beverage with standard nutritional protein.

OTHER

Negative Dose

Participants will consume a beverage with 15g less extended release protein than either the low dose cohort or the high dose cohort.

Sponsors & Collaborators

  • United States Department of Defense (DOD)

    collaborator UNKNOWN

  • VitaKey Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-17
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07313436 on ClinicalTrials.gov